Background-The border zone of healing myocardial infarcts is an arrhythmogenic substrate, partly the result of structural and functional remodeling of the ventricular gap junction protein, Connexin43 (Cx43). Cx43 in arrhythmogenic substrates is a potential target for antiarrhythmic therapy. Methods and Results-We characterized Cx43 remodeling in the epicardial border zone (EBZ) of healing canine infarcts 5 days after coronary occlusion and examined whether the gap junction-specific agent rotigaptide could reverse it. Cx43 remodeling in the EBZ was characterized by a decrease in Cx43 protein, lateralization, and increased Cx43 phosphorylation at serine (S) 368. Rotigaptide partially reversed the loss of Cx43 but did not affect the increase in S368 phosphorylation, nor did it reverse Cx43 lateralization. Rotigaptide did not prevent conduction slowing in the EBZ, nor did it decrease the induction of sustained ventricular tachycardia by programmed stimulation, although it did decrease the EBZ effective refractory period. Conclusions-We conclude that partial reversal of Cx43 remodeling in healing infarct border zone may not be sufficient to restore normal conduction or prevent arrhythmias. (Circ Arrhythm Electrophysiol. 2011;4:344-351.)
In addition to structural remodeling, functional remodeling of gap junctions, characterized by changes in the phosphorylation state of Cx43, is associated with pathology. 3 Phosphorylation at S325, S328, and S330 in the early gap junction life cycle is necessary for assembly of gap junction plaques, 4 and phosphorylation at S364 or S365 is important for trafficking to the plasma membrane. 5 Some of these sites have also been implicated in pathogenesis because their phosphorylation status is altered during acute ischemia and heart failure, 3, 6, 7 possibly leading to a decrease in Cx43. One additional site of interest is S368, which becomes phosphorylated during cellular stress, which may lead to a decrease in gap junction conductance. 8 Phosphorylation of Cx43 has not been studied in healing infarct border zone (EBZ). In this study, we further characterized Cx43 remodeling in EBZ by measuring Cx43 quantity and the involvement of phosphorylation at one site, S368.
It has been proposed that prevention or reversal of gap junction remodeling may be an effective antiarrhythmic intervention. An antiarrhythmic effect of the compound ZP123 (rotigaptide) has been demonstrated in acutely ischemic myocardium. 9, 10 One mechanism proposed for the effect of rotigaptide is altering phosphorylation of Cx43 at S368. 11 Therefore, we determined the effects of rotigaptide on Cx43 remodeling, phosphorylation at S368, and the associated electrophysiological changes in the EBZ. lar tachycardia (SMVT) can be initiated by programmed electrical stimulation, 1 and conduction velocity and refractoriness of the remodeled regions can be determined. 1, 2, 12, 13 Electrophysiological measurements were made before and after intravenous rotigaptide or saline infusion for 1 or 3 hours (see online-only Data Supplement).
Measurement of Na ؉ Current
Whole-cell voltage clamp techniques were used to determine the effects of rotigaptide on I Na of myocytes dispersed from 5-day EBZ using previously described methods. 14 In one series of experiments, the drug was infused into the cell chamber and Na ϩ current measured before and after the drug. In another series, Na ϩ current was measured after infusion of the drug in vivo for 3 hours.
Western Blot Analysis for Protein Levels
Tissue samples were obtained from EBZ of infarcted hearts with or without drug treatment and from a remote noninfarcted region on the posterior left ventricle of infarcted hearts, after the electrophysiological experiment was complete. Tissue was also taken from the left ventricular epicardium of 5 noninfarcted hearts. Western blot was run as previously described 15 (see online-only Data Supplement).
Immunohistochemistry
Rapidly frozen epicardial samples were sectioned (15 m), fixed in 4% paraformaldehyde, and immunostained as previously described 15 (see online-only Data Supplement).
Statistical Methods
Data are presented as meanϮSEM. Effective refractory period data were tested using a repeated-measures ANOVA. If significant changes occurred, means were compared using the Bonferroni method. A value of PϽ0.05 was significant. Conduction velocity was analyzed using a paired t test with a significance level of 0.05. Detailed statistical methods are described in the online-only Data Supplement.
Results

Characteristics of Cx43 Remodeling in EBZ and Effects of Rotigaptide
Western blot analysis showed that total Cx43 levels normalized for total protein, which represents mainly myocytes (see onlineonly Data Supplement), were decreased in the EBZ ( Figure 1A ). Rotigaptide caused a significant increase in Cx43 after 1 hour, but Cx43 remained significantly less (PϽ0.05) than normal. Additional treatment (3 hours) did not augment this increase. Phosphorylation of Cx43 on the serine residue 368 (pS368) occurs via activation of protein kinase C (PKC). Figure 1B shows that in normal canine epicardial tissue the amount of PKC is very low. PKC is significantly increased in the EBZ and rotigaptide did not reverse this increase ( Figure 1B) . In normal epicardium, the ratio of pS368 Cx43/total Cx43 is very low ( Figure 1C ). In the EBZ, phosphorylation at this residue was markedly increased ( Figure 1C ), and this increase remained significant after rotigaptide ( Figure 1C ).
Cx43 was also analyzed in epimyocardial samples from noninfarcted remote sites on the posterior wall from the same set of experiments. Cx43 levels were not significantly reduced (PϾ0.05). There was no significant change in Cx43 in the remote region after rotigaptide (data not shown).
A hallmark of Cx43 remodeling in EBZ is lateralization. 2 To determine if rotigaptide reversed it, we did immunostaining ( Figure 2 ) for Cx43 (red), using the scaffolding protein ZO-1 (green) as a marker of the intercalated disk. Myocytes in the EBZ exhibited lateralization of Cx43 (compare Cx43 norm and 5-day), whereas ZO-1 remained at the ID (compare ZO-1 norm and 5-day). The overlay image of Cx43 and ZO-1 shows that much of the Cx43 is no longer at the intercalated disk. Rotigaptide did not reverse the lateralization (compare 5-day, 1-hour, and 3-hour). The overlay images indicate that there were many areas that still had lateralized Cx43 (white arrows, 1 and 3 hours). The quantification of Cx43 lateralization shown in the bottom panel also shows a marked increase in lateralization at 5 days without reversal by rotigaptide. Lateralization did not occur in the remote posterior left ventricle of the infarcted hearts.
Effects of Rotigaptide on EBZ Conduction
Maps acquired during stimulation at the center of the large electrode array, which were used to measure conduction velocities over most of the EBZ ("global" conduction velocity), were characterized by elliptical isochrones with the long-axis parallel to the long axis of the myocardial fiber bundles. Figure 3 shows maps from one experiment, activation pattern in control before drug in Figure 3A , and after 3 hours of rotigaptide infusion in Figure 3B . Table 1 shows the global conduction velocities calculated from the large electrode array, in the longitudinal (CV L ) and transverse (CV T ) directions, and the anisotropic ratio (AR) for control and after 1 and 3 hours of rotigaptide infusion. There were no significant changes in any of the measured parameters at both time periods (PϾ0.05). Two sets of measurements were made with the small high-density electrode array ( Figure 3C and 3D) to determine local CV at 1 and 3 hours. As compared with control ( Figure 3C ) there were no significant changes in either CV L or CV T or ARs after 1 hour (Table 2) 
Effects of Rotigaptide on EBZ Effective Refractory Period
Rotigaptide significantly shortened effective refractory period (ERP) in the EBZ after 3 hours of infusion ( Figure 4A ) (control, 237.5Ϯ4.8 ms; 1 hour, 230.0Ϯ4.1 ms; 2 hours, 217.5Ϯ2.5 ms; 3 hours, 207.5Ϯ4.8 ms; PϽ0.05, 3-hour versus control ERP and 1 hour). In the experiments in which Figure 2 . Immunofluorescent-labeled myocytes for Cx43 (red) and ZO-1 (green). In normal hearts, Cx43 is localized almost exclusively with ZO-1 at the intercalated disk (Norm) (overlay). After 5-day infarction, lateralization of Cx43 is seen. Treatment with 1-hour or 3-hour rotigaptide did not alter lateralization (arrows show areas of lateralized Cx43). Quantification of Cx43 on lateral membranes (not associated with ZO-1) showed no significant effect of rotigaptide on lateralized Cx43 (nϭ3, bar graphs below, meanϮSEM; *PϽ0.05 compared with normal).
Figure 3. A and B,
Activation maps from stimulation of EBZ at the center of the large electrode array; 10-ms-interval isochrones are represented by colors progressing from earliest activation at the site of stimulation (red) to latest activation (dark blue). A, Control map at a basic cycle length (S1-S1) of 300 ms (CV L ϭ48 cm/s, CV T ϭ33 cm/s, ARϭ1.39); B, after 3-hour infusion of Rotigaptide (CV L ϭ40 cm/s, CV T ϭ25 cm/s, ARϭ1.68). C and D, Activation maps with high-density array during stimulation from the center at a cycle length of 300 ms. Color code is the same as in A and B; small numbers indicate activation times. The long axes of the elliptical isochrones indicate longitudinal activation (CV L) ; short axes indicate transverse activation (CV T ). C, Activation map during control (CV L ϭ35 cm/s, CV T ϭ15 cm/s, ARϭ2. 19 As a result of ERP shortening, conduction of premature impulses was facilitated ( Figure 4B and 4C). Figure 4B shows the conduction pattern of a control premature impulse with a coupling interval of 260 ms, the shortest coupled impulse that propagated in this experiment. Figure 4C shows conduction of a premature impulse at a coupling interval of 220 ms, the earliest propagated premature impulse after the 3-hour rotigaptide infusion, indicating a decrease in the ERP of 40 ms. At this shorter coupling interval, conduction velocities in both longitudinal and transverse directions are similar to control velocities at the 260-ms coupling interval. Similar effects were found in all other experiments.
Effects of Rotigaptide on SMVT
Rotigaptide did not have a consistent antiarrhythmic effect. In the 8 experiments in which rotigaptide was infused for either 1 or 3 hours, SMVT was induced in 4 either from the EBZ or the right ventricular stimulation site ( Figure 5 ). SMVT was caused by reentrant excitation that was mapped in the EBZ ( Figure 6A ).
Cycle length ranged from 170 to 300 ms. In 3 of these experiments in which there was a 3-hour infusion period, SMVT was still inducible at the end of the 3 hours ( Figure 5 ), although the pattern of excitation of the EBZ sometimes changed ( Figure  6 ). There were no changes or only small changes in the programmed electrical stimulation coupling values at which SMVT was induced after the drug. In experiment 1, SMVT was induced in control with rapid pacing from the center site at a cycle length of 260 ms. After rotigaptide for 2 hours, it was still induced at a pacing cycle length of 260 ms and after 3 hours at a pacing cycle length of 240 ms. In experiment 2, SMVT was induced in control from the right ventricular site with double extrastimuli (280 basic cycle length [BCL]/170 S2/165 S3) and after 3 hours of rotigaptide at 280 BCL/180 S2/165 S3 (ERP at the normal stimulation site increased by about 8 ms). In experiment 3, SMVT was induced from the right ventricular site by single premature stimuli in control (350 BCL/220 to 200 S2), after 2-hour rotigaptide (350 BCL/220 S2), and after 3-hour rotigaptide (350 BCL/190 S2).
SMVT cycle length decreased in 2 of these experiments (170 ms in control to 160 ms in rotigaptide; 300 ms in control to 230 ms in rotigaptide) and increased in 1 experiment (235 ms in control to 247 ms in rotigaptide). In the experiment shown in Figure 5 , the increased cycle length despite a shortening of the ERP was related to a change in the activation pathway during reentry.
In the other (4th) experiment in which SMVT was induced in control, it could not be induced at 1 hour despite testing with the exact same programmed electrical stimulation protocol. Drug infusion was not continued beyond this time period. In 2 experiments in which SMVT could not be initiated in control, it was initiated after 1 and 3 hours of rotigaptide infusion. SMVT was initiated in 2 of 4 saline experiments. In 1 experiment it could be reinduced periodically for the 3 hours of saline infusion, whereas in the other it could not be induced after 1 to 3 hours of saline infusion. In the other 2 experiments in which SMVT was not induced in control, it was also not induced after 3-hour saline infusion.
Effects of Rotigaptide on Remodeled Na ؉ Currents of EBZ Myocytes
To determine if rotigaptide might decrease Na ϩ current to offset possible effects of improved gap junction coupling on conduction or alter recovery from inactivation to influence ERP, myocytes isolated from the EBZ were voltage-clamped, peak I Na was recorded, 14 and the cells were then exposed to rotigaptide (80 nmol/L) for 30 minutes. There was no significant effect of drug on peak I Na (nϭ4; predrug, 4.01Ϯ0.63 pA/pF; ϩ30 minutes, 3.48Ϯ0.50 pA/pF; V h ϭϪ100 mV) or recovery from inactivation (nϭ4) (data not shown). In an additional 3 myocytes dispersed from the EBZ that had been exposed to 3 hours of rotigaptide infusion, we found peak I Na (5.54Ϯ1.84 pA/pF) to be similar to previously published I Na data for EBZ myocytes. 14 There was no evidence for a direct depressant effect of rotigaptide on peak sodium current function.
Discussion
We investigated gap junction remodeling in EBZ and the possibility of reversing it to improve conduction and prevent arrhythmias using rotigaptide as a pharmacological tool, based on it increasing gap junction coupling during metabolic stress and acute ischemia. 9,10, 16 We found a significant reduction of total Cx43 in EBZ, with an increase in phosphorylation at residue S368, which has been associated with a decrease in gap junctional conductance. 17 In contrast to previous studies on acute ischemia, 9, 10 rotigaptide partially reversed Cx43 remodeling in EBZ by increasing Cx43. However, rotigaptide did not affect conduction velocity nor prevent induction of SMVT, although it did decrease the ERP.
Gap Junction Remodeling in Infarct Border Zones
Serine and tyrosine phosphorylation sites in the Cx43 molecule participate in functional regulation. 18 Tyrosine phosphorylation is associated with channel closure. 18 Acute ischemia leads to loss of Cx43 phosphorylation at S325, S328, and S330, accompanied by a decrease in Cx43 protein and lateralization of Cx43. 4, 6, 7 Dephosphorylation at those sites and the decrease in protein contribute to decreased cell-to-cell coupling, manifested as an increase in resistivity within 15 to 20 minutes of acute ischemia. 19 Dephosphorylation of Cx43 at S364/365 also occurs rapidly within 5 minutes. Other sites that are dephosphorylated during acute ischemia are S297 and S306, 11, 20 which may contribute to decreased coupling. In contrast, serine residue S368 becomes phosphorylated during acute ischemia as a result of activation of PKC. 5, 17, [21] [22] [23] This occurs only after dephosphorylation of a "gatekeeper" serine, S365, 24 which in its normal phosphorylated state inhibits phosphorylation of S368. Once S365 is dephosphorylated, S368 is accessible for PKC phosphorylation, which causes decreased channel conductance. 23 This regulation is important for ensuring that gap junctional conductance is not decreased by other signaling pathways that may activate PKC. The above changes occur in acutely ischemic myocardium, much of which dies and forms the infarct core. Gap junction remodeling also occurs in infarct border zones, which form arrhythmogenic regions. 1, 2 During the healing phase of infarction, Cx43 lateralization persists in the EBZ. 2 Within several hours of coronary occlusion, the separation of Cx43 from ZO-1 that is caused by the decreased intracellular pH is a primary step in the movement of Cx43 to the lateral membranes, probably leading to its eventual internalization and destruction. 15 Lateralization continues to be present at 5 days. 2, 13 The increase in PKC that we measured in the EBZ at this time might lead to compromised Cx43 targeting/retention at intercalated disks, resulting in lateralization and the marked decrease in Cx43. 22, 25 The increased phosphorylation of the remaining Cx43 at S368, which has not been previously described in EBZ, may contribute to decreased gap junctional coupling. 26
Relationship of Gap Junction Remodeling to EBZ Arrhythmogenic Electrophysiology
Cx43 remodeling in EBZ contributes, along with ion channel remodeling, to altered electrophysiology that leads to this site being an arrhythmogenic source. The EBZ in healing infarcts is characterized by nonuniform anisotropic conduction. 1 Control conduction velocities in Tables 1 and 2 are in agreement Figure 4 . A, Effective refractory periods (EBZ-RP) in control before rotigaptide infusion (Ctr, circles; nϭ4) and 1 hour (squares; nϭ4), 2 hours (diamonds; nϭ4), and 3 hours (triangles; nϭ4) after infusion. Data from each individual experiment are represented by a different color (black, red, yellow, and green). MeanϮSEM value at each time is represented by unfilled symbols with error bars. *PϽ0.05, 3 hours versus Ctr, and #PϽ0.05, 3 hours versus 1 hour determined by repeated-measures ANOVA/Bonferroni. B, Activation of the earliest propagated premature impulse in control (S1-S2ϭ260 ms). C, Activation of the earliest propagated premature impulse after 3 hours of rotigaptide infusion (S1-S2ϭ220 ms), when ERP was decreased. Longitudinal activation (arrows) is similar before and after rotigaptide. with our previous studies. 12, 13 Gap junction conductance in the transverse direction is decreased in EBZ myocytes despite an increase in lateralized Cx43, suggesting that lateralized Cx43 does not form functional gap junctions. 26 The decrease in conductance may be related to the decreased Cx43 and increased S368 phosphorylation that we show in this study. The 76% decrease in Cx43 quantity has been shown to slow conduction. 27 The precise relationship of the reduction in Cx43 protein to slowed conduction is not straightforward, owing to a contribution from decreased Na ϩ current 14 and structural changes (separation of myocardial fiber bundles by edema) that may disrupt gap junction connections. 28 The EBZ is also characterized by a prolonged ERP that facilitates block of premature impulses that initiate SMVT. 29 Computer modeling has shown that gap junction coupling can influence time course for repolarization in regions where intrinsic repolarization of myocytes is heterogeneous, 30 -32 making repolarization and ERP more homogeneous. 33 Uncoupling of myocytes prolongs repolarization in these models and has been proposed to underlie ERP prolongation in the epicardium in heart failure, where Cx43 is reduced. 34 Such uncoupling may contribute to prolongation of the ERP in the EBZ, although remodeling of reactivation kinetics of Na ϩ currents also contributes to postrepolarization refractoriness. 14
Reversal or Prevention of Cx43 Remodeling as an Antiarrhythmic Intervention
Because gap junction remodeling contributes to arrhythmogenesis, 3 preventing the reduction in gap junction coupling that accompanies it may have antiarrhythmic effects. Rotigaptide has been touted to do this, based on experiments showing that it prevents the decrease in conduction velocity caused by acute ischemia and metabolic stress [35] [36] [37] without affecting sarcolemmal ion channels. 16, [37] [38] [39] This effect has been associated with the prevention of reentrant ventricular and atrial arrhythmias associated with acute ischemia. 9, 10, 40 It has been proposed that rotigaptide exerts its effects by PKC activation to prevent dephosphorylation (or induce rephosphorylation) of Cx43 during acute ischemia. 39 -41 Emphasis has been placed on rotigaptide-mediated phosphorylation at S368, which was found to be dephosphorylated in an acute global ischemia rat model. 11 These findings are contrary to studies cited above, which showed enhanced phosphorylation of S368 in acute ischemia and the present study ( Figure 1 ). We believe this discrepancy occurs because total Cx43 is dramatically reduced in ischemia; thus, overall levels of phosphoCx43 are reduced. The increase in phosphorylation at this residue then can only be discussed in terms of the percentage of Cx43 that is phosphorylated at S368. In normal heart, the percentage of pS368/total Cx43 is quite low. In contrast, in the EBZ, there is a dramatic increase in the percentage of Cx43 that is phosphorylated at S368. This indicates that not only is total Cx43 decreased, the remainder of the Cx43 is primarily phosphorylated at S368.
Because rotigaptide increases gap junction conductance 42 and prevents acute ischemic arrhythmias, 9 we investigated whether the drug would have similar effects in healing infarction. Rotigaptide partially reversed Cx43 remodeling in EBZ, as evidenced by increased Cx43 quantity at 1 hour (Figure 1) , an effect not previously shown in models of acute ischemia or metabolic stress. This was unrelated to any effect on PKC or phosphorylation at S368, which remained elevated and unchanged. However, it may have been related to phosphorylation at other sites that control Cx43 life cycle, which we did not measure, or increases in transcription/ translation. Because lateralization of Cx43 is related to degradation 15 and was not affected, it is unlikely that reduction of degradation applies to the effects of rotigaptide. At 3 hours, the increase in Cx43 was not significant compared with control (but also not significantly different than at 1 hour), indicating that either sample size was too small, variability was too large, or the effects at 1 hour wanes with time.
Conduction velocity in EBZ did not increase despite the increased Cx43. It is uncertain whether the increased Cx43 formed functional gap junctions. Because Cx43 remained highly phosphorylated at S368, if gap junctions were formed, they still may have reduced conductance characteristic of pS368 Cx43 gap junctions. If some of the increased Cx43 was lateralized, it also would not be expected to be functional, although we did not detect an increased lateralized Cx43. In addition, conduction slowing in EBZ is also a result of remodeled Na ϩ current, which was not affected by rotigaptide. Failure to improve conduction velocity was not a result of depression of Na ϩ current by rotigaptide to negate an effect of increasing gap junction conductance. Our results are consistent with other studies showing that rotigaptide is not effective when structural remodeling and/or ion channel remodeling of the arrhythmogenic substrate has occurred. 37, 40, 43 Nevertheless, rotigaptide reduced the ERP, which was specific for the EBZ because it did not occur in normal ventricle. This effect, which has also been described in chronic human heart failure, 43 may have been an indicator of some restoration of gap junction coupling, reversing ERP prolongation caused by uncoupling (see above discussion on gap junction uncoupling and repolarization). Rotigaptide did not affect reactivation kinetics of the Na ϩ channel, but we cannot rule out an effect on repolarizing ionic currents in EBZ myocytes, although it has not been seen in normal myocytes.
Rotigaptide did not prevent SMVT in 3 of 4 experiments. There were small changes in coupling intervals of stimulated impulses inducing SMVT. Whether that had any effect on inducibility is uncertain, but we interpret these results to indicate that the drug did not have a robust effect to prevent SMVT. It is possible that in a larger series of experiments, it would exhibit some antiarrhythmic activity. The failure to prevent induction of SMVT may be related to persistence of conduction abnormalities in the EBZ. Whether the changes in SMVT cycle lengths or patterns of reentry were related to an effect of rotigaptide is uncertain. In 2 experiments, SMVT was inducible only after rotigaptide. More experiments are necessary to determine if it has a significant proarrhythmic effect.
Conclusion
Improving myocyte coupling is an attractive idea for a new approach to antiarrhythmic therapy. The results of our study indicate that interventions that are effective in restoring cell-tocell coupling under conditions of acute ischemia may not be effective in a substrate that has already undergone a prolonged period of gap junction remodeling such as the border zone of healing infarcts. Drugs with properties that would restore coupling in this environment might still be effective.
